SecBot SecBot
8-K ·Filed May 12, 2026

IMNM

Immunome Inc.
BULLISH
Impact 7/10
Horizonweeks Processed6mo ago SEC0001193125-26-219367
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The EPS beat and NDA submission are positive catalysts. Watch for ASCO presentation (June 2026) and potential FDA acceptance of NDA. The cash runway into 2028 removes near-term financing risk. Monitor for any regulatory updates on varegacestat and initial data from IM-1021 later in 2026.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$22.20
T+0 close · May 12, 2026 · via day close
Latest settled
+12.75%
T+60 · $25.03
Vs SPY
+8.31%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 13 $22.20entry
  2. T+1 · 6mo ago 0.00%α +0.00% · $22.20
  3. T+5 · 6mo ago −11.44%α −10.28% · $19.66
  4. T+20 · 5mo ago −17.30%α −16.68% · $18.36
  5. T+60 · 3mo ago +12.75%α +8.31% · $25.03
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Immunome reported Q1 2026 results: net loss of $53.8M ($-0.48/share) vs consensus $-0.60, a beat of 20% on EPS. The NDA submission for varegacestat in desmoid tumors is the key catalyst, with ASCO oral presentation and EU MAA planned. Cash runway into 2028 supports pipeline execution.

Key Financial Metrics

EPS
−$0.48
est −$0.60 · +20.0%
Revenue
$0.00
est $167.0K · -100.0% · -100.0% YoY
Rating
beat

Key Facts

  • NDA submitted to FDA for varegacestat in desmoid tumors (April 2026)
  • Phase 3 RINGSIDE data selected for oral presentation at ASCO 2026
  • Q1 2026 net loss $53.8M ($-0.48/share) vs consensus $-0.60, 20% beat
  • Cash and equivalents $582.7M, runway into 2028
  • IND clearance received for IM-1617 (solid tumor ADC) in April 2026
  • Phase 1 trial of IM-3050 (FAP-targeted radiotherapy) initiated March 2026
  • Collaboration revenue declined to $0 from $2.9M YoY (prior period had revenue)

Financial Impact

EPS beat of 20% vs consensus; cash burn $53.8M/quarter; $582.7M cash position

epscashoperating expenses

Risk Factors

  • FDA regulatory risk for varegacestat NDA, no guarantee of approval
  • No collaboration revenue in Q1 2026 vs $2.9M in Q1 2025
  • Operating loss widening to $59.3M from $44.6M YoY
  • Pre-revenue biotech, entirely dependent on pipeline success

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
95% bullish (20 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-219367
Document: imnm-20260512.htm0001193125-26-219367
Document: 0001193125-26-219367-index-headers.html0001193125-26-219367
Document: 0001193125-26-219367-index.html0001193125-26-219367
Document: 0001193125-26-219367.txt0001193125-26-219367
8-K Data (Synthetic)0001193125-26-219367

US Market Status

Market Closed · Opens in 6h 35m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 12, 2026